• In early June 2026, Alkermes reported a narrower-than-expected first-quarter loss and stronger revenue, supported by higher sales of Vivitrol, Aristada, Lybalvi, and newly acquired Lumryz, while reaffirming its full-year revenue guidance despite increased R&D and acquisition-related spending.
• By pairing solid proprietary product trends with encouraging new data for orexin agonist alixorexton, the company is increasingly framing sleep medicine as a core pillar of its evolving business story.
• Next, we’ll examine how Lumryz’s contribution and positive alixorexton data might influence Alkermes’ existing investment narrative and risk profile.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Alkermes Investment Narrative Recap

To own Alkermes, you need to believe its focused CNS portfolio can support both the current psychiatry franchise and an emerging sleep-medicine pillar. The latest results, with stronger revenue and a narrower loss, reinforce that view but do not remove near term pressure around rising R&D and orexin trial execution, which remain the key catalyst and the biggest risk in the story right now.

Among recent updates, the positive Phase 2 Vibrance-1 data for orexin agonist alixorexton stand out as most relevant. Together with Lumryz, these results give more substance to Alkermes’ effort to make sleep medicine a core business line, but they also increase reliance on successful late stage development and future regulatory decisions around the Brilliance Phase 3 program.

Yet beneath the stronger quarter, investors should still be aware of how much hinges on orexin trial outcomes and evolving safety scrutiny around...

Alkermes' narrative projects $2.1 billion revenue and $238.9 million earnings by 2029.

Uncover how Alkermes' forecasts yield a $44.24 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$2.6 billion and earnings near US$790 million by 2029, so this new sleep data could either support those expectations or highlight just how much their upbeat view depends on alixorexton avoiding the kind of late stage or regulatory setbacks you need to weigh for yourself.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth 13% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.